The German Revotar Biopharmaceuticals AG has started a trial Phase II of its Bimosiamose cream 5%. The cream was safe and well tolerated by study Phase I. The
Bimosiamose is a new potent synthetic inhibitor of all selectins (P, E, L), molecules that are fundamental in nell'attachment leukocyte rolling and migration during vascular endothelium at sites of inflammation.
Bibliography:
Bimosiamose AND psoriasis on PubMed
0 comments:
Post a Comment